Related Experiment Video

Updated: Jun 5, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Novel approaches and future directions in castration-resistant prostate cancer

C Nabhan1, B Parsons1, E Z Touloukian2

  • 1Department of Medicine, Division of Hematology and Oncology, Lutheran General Hospital, Park Ridge.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 22, 2011
PubMed

Insights

New treatments are improving outcomes for castration-resistant prostate cancer (CRPC). This review explores non-chemotherapy options targeting key pathways, offering hope for better disease control in prostate cancer (PCA).

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer (PCA) treatment has evolved, with recent advances in castration-resistant prostate cancer (CRPC).
  • Understanding resistance mechanisms is crucial for developing targeted therapies.
  • Chemotherapy offers modest success, necessitating novel treatment strategies.

Purpose of the Study:

  • To review the mechanisms driving PCA to a castration-resistant state.
  • To elaborate on emerging non-chemotherapy treatments for CRPC.
  • To highlight recent therapeutic advancements for improved disease control.

Main Methods:

  • Review of current literature on CRPC mechanisms and treatments.
  • Discussion of novel therapeutic targets and agents.
  • Synthesis of information on non-chemotherapy approaches.

Main Results:

  • Identification of key pathways involved in castration resistance.
  • Elaboration on diverse non-chemotherapy treatment modalities.
  • Confirmation of a shift towards more effective CRPC therapies.

Conclusions:

  • Advances in understanding CRPC mechanisms enable rational therapeutic design.
  • Non-chemotherapy approaches represent a significant evolution in CRPC treatment.
  • Emerging therapies offer improved prospects for disease management in prostate cancer.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...